Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS
mi
from
Philadelphia, PA
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated:  12/31/1969
Pitt CRS
mi
from
Pittsburgh, PA
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated: 12/31/1969
Pitt CRS
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients
Status: Enrolling
Updated:  12/31/1969
Walter Reed Army Medical Center
mi
from
Washington,
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients
Status: Enrolling
Updated: 12/31/1969
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Usc La Nichd Crs
mi
from
Alhambra, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Usc La Nichd Crs
mi
from
Alhambra, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Miller Children's Hosp. Long Beach CA NICHD CRS
mi
from
Long Beach, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Miller Children's Hosp. Long Beach CA NICHD CRS
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
mi
from
Los Angeles, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
UCSD Mother-Child-Adolescent Program CRS
mi
from
San Diego, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
UCSD Mother-Child-Adolescent Program CRS
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of California San Francisco NICHD CRS
mi
from
San Francisco, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of California San Francisco NICHD CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Colorado Denver NICHD CRS
mi
from
Aurora, CO
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Colorado Denver NICHD CRS
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's National Med. Ctr. Washington DC NICHD CRS
mi
from
Washington,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's National Med. Ctr. Washington DC NICHD CRS
mi
from
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Miami Ped. Perinatal HIV/AIDS CRS
mi
from
Miami, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Miami Ped. Perinatal HIV/AIDS CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
mi
from
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Chicago Children's CRS
mi
from
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Chicago Children's CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital
mi
from
New Orleans, LA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hosp. of Boston NICHD CRS
mi
from
Boston, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hosp. of Boston NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
WNE Maternal Pediatric Adolescent AIDS CRS
mi
from
Worcester, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
WNE Maternal Pediatric Adolescent AIDS CRS
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Michigan NICHD CRS
mi
from
Detroit, MI
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Michigan NICHD CRS
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Rutgers - New Jersey Medical School CRS
mi
from
Newark, NJ
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Rutgers - New Jersey Medical School CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Bronx-Lebanon CRS
mi
from
Bronx, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Bronx-Lebanon CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
mi
from
Brooklyn, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Nyu Ny Nichd Crs
mi
from
New York, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Nyu Ny Nichd Crs
mi
from
New York, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Strong Memorial Hospital Rochester NY NICHD CRS
mi
from
Rochester, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Strong Memorial Hospital Rochester NY NICHD CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
SUNY Stony Brook NICHD CRS
mi
from
Stony Brook, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
SUNY Stony Brook NICHD CRS
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
DUMC Ped. CRS
mi
from
Durham, NC
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
DUMC Ped. CRS
mi
from
Durham, NC
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
St. Jude/UTHSC CRS
mi
from
Memphis, TN
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
St. Jude/UTHSC CRS
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hosp. CRS
mi
from
Houston, TX
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hosp. CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital CRS
mi
from
Seattle, WA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
mi
from
San Juan,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
mi
from
San Juan,
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Usc Crs
mi
from
Los Angeles, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Usc Crs
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Stanford CRS
mi
from
Palo Alto, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Stanford CRS
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Ucsd, Avrc Crs
mi
from
San Diego, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Ucsd, Avrc Crs
mi
from
San Diego, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS
mi
from
Torrance, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS
mi
from
Torrance, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS
mi
from
Miami, FL
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Ctr. CRS
mi
from
Atlanta, GA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
IHV Baltimore Treatment CRS
mi
from
Baltimore, MD
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
IHV Baltimore Treatment CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Bmc Actg Crs
mi
from
Boston, MA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Bmc Actg Crs
mi
from
Boston, MA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Washington U CRS
mi
from
Saint Louis, MO
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Washington U CRS
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
NY Univ. HIV/AIDS CRS
mi
from
New York, NY
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
NY Univ. HIV/AIDS CRS
mi
from
New York, NY
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Columbia P&S CRS
mi
from
New York, NY
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Columbia P&S CRS
mi
from
New York, NY
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Trillium Health ACTG CRS
mi
from
Rochester, NY
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Trillium Health ACTG CRS
mi
from
Rochester, NY
Click here to add this to my saved trials